bial regimens for the treatment of acute maxillary sinusitis involves 1 of 3 sets of diagnostic criteria. In the most common clinical trial approach, 2 diagnostic criteria are used, one of which is a clinical diagnosis and the other of which is a plain film radiograph or CT scan with positive findings [1] [2] [3] . A second and common clinical trial approach not only involves clinical diagnosis and radiological documentation as baseline diagnostic criteria, but also involves obtaining a baseline sinus specimen for Gram stain and culture via a maxillary sinus puncture [4, 5] . A third and rare approach involves obtaining 2 sinus specimens for Gram stain and culture, one before initiation of antimicrobial therapy and the other several days after the end of therapy [6] . Irrespective of the diagnostic criteria used, clinical and/or microbiological response determination generally occurs 7-14 days after the end of antimicrobial therapy. Unfortunately, none of these clinical trial approaches provides any information concerning the time course of sinus sterilization or information regarding the extent of microorganism exposure to an antimicrobial agent at the infection site.
Serial acquisition of biological samples from the infection site, when technically feasible, may allow for documentation of drug effect with relatively few patients, compared with the number of patients required in traditional clinical trial approaches. The requirement of fewer patients arises from the use of continuous and quantitative end points, such as time to the sterilization of the infection site, rather than the dichotomous and nonspecific end points of clinical or microbiological cure or failure. Moreover, serial acquisition of biological samples from the infection site may permit the pharmacokinetic characterization of an antimicrobial agent at its effect site. Such data may allow for the construction of more-precise exposure-response relationships between measurement of organism exposure to an antimicrobial agent in individual patients and time to clinical and microbiological response.
In this study, we used a new technique to determine the time course of gatifloxacin effect in the treatment of acute maxillary sinusitis. This approach involved the insertion of an indwelling catheter into the maxillary sinus, which allowed for serial sinus aspirate sampling (SSAS). Our purpose was to describe the time course of sinus sterilization, clinical resolution of infection signs and symptoms, and gatifloxacin exposure at the infection site, with the hypothesis that the use of continuous and quantitative end points would allow for better characterization of drug effect.
PATIENTS AND METHODS
This pilot study was performed in compliance with an institutional review board, the Code of Federal Regulations standards, and the principles of the Declaration of Helsinki and its amendments. The trial was a single-center, open-label study evaluating the pharmacokinetics of gatifloxacin and the time course of its microbiological effect in adult patients with acute maxillary sinusitis.
Patient population. To be eligible for enrollment in this study, all patients must have been considered appropriate candidates for outpatient treatment and were required to meet all of the following criteria: facial pain and/or tenderness over one or both maxillary areas and either purulent discharge from the maxillary sinus orifice or purulent discharge from the nose or purulent discharge present in the back of the throat; radiological documentation confirming the clinical diagnosis of sinusitis, whereby the radiographs were considered supportive of the diagnosis if у1 of the following was evident in 1 or both maxillary sinuses: opacification or an air/fluid level or mucosal thickening of у5 mm; у18 years of age; and written and dated informed consent obtained from the patient or a legally authorized representative.
Patients were excluded from the study for any 1 of the following reasons: complicated sinusitis; recent (i.e., within 3 months before enrollment) sinus surgery; nosocomial sinusitis secondary to trauma or nasotracheal intubation; known renal insufficiency; known hepatic insufficiency; a previous hypersensitivity reaction to a quinolone; previously diagnosed disease(s) of immune function; or exposure to an investigational drug within 30 days before the first dose of study medication.
Clinical procedures. At enrollment, a full medical history was recorded, and a nasal examination was conducted. Patients were seen daily during therapy for clinical evaluation, drug administration, and recording of subjective and objective adverse events. Additionally, patients were seen 7-14 days after the end of antimicrobial therapy for a final clinical response evaluation and both subjective and objective adverse event recording. Patients received 400 mg of oral gatifloxacin every 24 h for 5 days.
On study day 1, the inferior meatus of the nose on the diseased side was anesthetized with topical xylocaine 4%, and oxymetazoline HCl 0.05% was instilled onto the sinus mucosa using cotton pledgets. After ∼10 minutes, the pledgets were removed, and ∼2 mL of 2% xylocaine with 1:100,000 epinephrine was injected into the mucosa of the lateral nose in the inferior meatus. A polyethylene catheter was then inserted into the maxillary sinus a few centimeters above the sinus floor using a spring-activated puncture device (SinoJect; Atos Medical). Use of this device allowed for controlled penetration into the sinus, which decreased the risk of deep penetration. Once the catheter was in place, an aspirate of sinus fluid was collected into a specimen transport tube, and a thin layer smear of the specimen was placed on a glass slide. All specimens were rapidly forwarded to the microbiology reference laboratory (The Jones Group/JMI Laboratories; North Liberty, IA). Daily sinus aspirates were then obtained on each of the next 4 days for microbiological evaluation.
On study day 3 or 4, 6 serial blood samples and 6 serial aspirates of sinus fluid were obtained for pharmacokinetic evaluation immediately before and 0.5, 1, 2, 4, and 6 h after gatifloxacin dosing. Blood samples were drawn into heparinized polypropylene tubes, cooled, and centrifuged for 10 min at 100 g and 5ЊC, and the separated plasma samples were immediately frozen. Each sinus aspirate was collected ∼30 s after 1-2 mL of preservative-free saline was instilled into the sinus via the catheter. Sinus aspirates were frozen immediately after they were obtained. Subsequently, serum and sinus aspirates were transported in frozen packs to Hartford Hospital (Hartford, CT) and then stored at Ϫ20ЊC until assayed. On study day 5, the indwelling catheter was removed from the sinus, and a follow-up evaluation was scheduled for 7-14 days after study day 5.
Outcome measures. To be considered clinically evaluable, patients were required to have met all of the inclusion criteria and none of the exclusion criteria, to have received у3 consecutive days of gatifloxacin therapy, and to have been evaluated 7-14 days after the end of therapy. Clinical response to therapy was determined by comparing the patients' baseline signs and symptoms of infection with those after therapy and was categorized as either cure or treatment failure. "Cure" was defined as resolution or improvement of all signs and symptoms present at study entry 7-14 days after the end of therapy without the need of further antibiotics. "Treatment failure" was defined as у1 of the following circumstances: persistent or worsened signs and symptoms of infection after у3 days of gatifloxacin therapy, new clinical findings consistent with progression of infection, lack of improvement or progressed abnormal radiological findings, and additional antibiotic therapy needed for the study indication. Microbiological response to therapy was evaluated daily during the 5-day treatment period and was classified as either eradicated or persistent. "Eradicated" was defined as the absence of the initial pathogen from all subsequent sinus aspirate cultures. "Persistent" was defined as the presence of the initial pathogen in the final culture.
Microbiological laboratory procedures. On receipt of the samples at the microbiology reference laboratory, Gram staining was performed, and semiquantitative cultures of the sinus fluid were processed and interpreted by routine methods. All bacterial pathogens isolated from the cultures were identified using routine biochemical tests and/or Vitek System (bioMérieux). Susceptibility testing was performed by the broth microdilution method recommended by the NCCLS [7] . Results of tests for individual antimicrobial agents were interpreted using NCCLS criteria [8] . All bacterial isolates were stored in trypticase soy broth with 20% glycerol or defibrinated rabbit blood at Ϫ70Њ C for further epidemiologic and molecular studies.
Gatifloxacin assay procedures.
Gatifloxacin concentrations in plasma samples and sinus aspirates were determined by high performance liquid chromatographic assay. The linear range of the standard curve for plasma was 0.05-5.0 mg/L. The accuracy and precision of the assay value were sufficient for the pharmacokinetic analysis; the within-day and between-day coefficients of variation were !4.6% and !3.94%, respectively. For sinus aspirates, the linear range of the standard curve was 0.03-5.0 mg/L, and the within-day and between-day coefficients of variation were !2.3% and !1.7%, respectively.
A urea dilution method, as described by Rennard et al. [9] was used to calculate sinus aspirate gatifloxacin concentration, ( , where SAG is the gatifloxacin concentration SAG ϫ BU)/SU in sinus aspirate, BU is the blood urea concentration, and SU is the sinus urea concentration. Urea concentrations were determined using a commercial diagnostic kit (Urea Nitrogen Quantification; Sigma). The linear range of the standard curves was 0.1-12 mg/dL, and the within-day and between-day coefficients of variation were !10.5% and !5.58%, respectively.
Pharmacokinetic analysis. Individual plasma sample and sinus aspirate gatifloxacin concentration-time profiles were modeled using NONMEM software, version 5.1, level 1.1 (University of California at San Francisco) [10] . Gatifloxacin plasma concentrations were described using a 1-compartment model with first-order absorption and elimination; an absorption lagtime was incorporated into the model for some patients. Inclusion of this parameter in the model resulted in an improved fit for 3 patients. Gatifloxacin concentrations in sinus aspirates were simultaneously described using a variation of the biophase model [11] . Because effect-site concentrations were available, the transfer rate constant from the plasma to the sinus compartment and the elimination rate constant from the sinus compartment were modeled independently. Residual variability was described using separate additive error models for sinus and plasma concentrations.
To estimate plasma and sinus exposure (maximum concentration [C max ] and area under the concentration-time curve [AUC]), the individual parameter estimates were used to create predicted concentration-time profiles with samples obtained every 30 min from 0 to 24 h. From these predicted profiles, AUC was calculated using the trapezoidal rule, C max was defined as the maximum predicted concentration, and T max was the time at which that concentration occurred.
Statistical analysis. Descriptive statistics were generated for all data collected, including patient demographic characteristics and medical history, vital signs, adverse events, plasma sample and sinus aspirate drug concentrations, and appropriate pharmacodynamic measurements. The primary efficacy end points of the study were time from start of therapy to bacteriological eradication of pathogens from the maxillary sinus and time to clinical resolution of individual signs and symptoms. Estimates of the resolution rates were obtained using the Kaplan and Meier product-limit method, and 95% CIs for these estimates were obtained using the method of Brookmeyer and Crawley [12] . To gain insight into potential sample sizes for comparative clinical trials using time to eradication rather than clinical success or failure as the primary end point, we estimated a power to detect clinically important differences with a type I error (a) of 0.05 for various sample sizes. All statistical analyses and sample size calculations were performed using SAS software, version 8.2 (SAS Institute), and nQuery Advisor software, version 4.0 (Statistical Solutions), respectively. 
RESULTS

Patients, clinical response to therapy, and adverse events.
A total of 12 patients (6 white men and 6 white women) were enrolled in this pilot study. The mean ‫ע(‬ SD) patient age was 48.3 ‫ע‬ 15.3 years, with a mean ‫ע(‬ SD) height and weight of 172.6 ‫ע‬ 7.9 cm and 73.6 ‫ע‬ 11.2 kg, respectively. Of the 12 patients, 10 were evaluable for clinical response. One patient was characterized as clinically unevaluable because of failure to undergo an evaluation after treatment, and the other patient received inadequate antibiotic dosing. Microbiologically evaluable patients were the subset of clinically evaluable patients who also had a microorganism identified from culture of sinus aspirate fluid. The microorganisms isolated included Streptococcus pneumoniae (4 isolates), coagulase-negative staphylococci (2 isolates), and Enterobacter aerogenes (1 isolate). The MIC of gatifloxacin for the isolated microorganisms was 0.12-0.5 mg/L. For S. pneumoniae, MIC values were either 0.25 mg/ L (for 3 isolates) or 0.5 mg/L (for 1 isolate), and 1 isolate was penicillin-resistant, with an MIC of penicillin of 0.25 mg/L . Sinus catheters were inserted with minimal discomfort and were well tolerated. A Waters' projection showing a catheter inserted into the right maxillary sinus is presented in figure 1 . Adverse events were generally mild and transient in nature. No serious adverse events occurred during the study.
Pharmacokinetic analysis. Of the 10 clinically evaluable patients, 7 had sufficient pharmacokinetic data for analysis. The median parameter estimates were used to generate a predicted gatifloxacin concentration-versus-time profile in plasma samples and sinus aspirates at steady state, as shown in figure 2. The time to the peak concentration in sinus aspirates was longer and the peak was broader than in plasma samples. Table 1 shows median pharmacokinetic parameter estimates in plasma samples and sinus aspirates. The median predicted 24 h AUCs for plasma samples and sinus aspirates were 30.1 and 54.7 mg ϫ h/L, respectively. The median 24-h AUC sinus:plasma ratio was 1.51 (range, 0.88-2.23). The plasma pharmacokinetic parameter estimates were similar to those previously reported in healthy volunteers [13] .
Pharmacodynamic analyses. For the patients with pneumococci isolated, the time to sinus sterilization was 24-74 h. Figure 3 shows an inverse Kaplan-Meier plot of the proportion of patients with pneumococcal bacteriologic eradication on each study day. The median time to resolution was 50 h. Daily Gram stain and semiquatitative culture results are presented in table 2 for the 4 patients with S. pneumoniae isolated. Concordance between Gram stain results and culture results was 100%.
For the patients with pneumococci isolated, the median time to clinical resolution of individual symptoms was 24-72 h, with 28 (88%) of 32 signs and symptoms having resolved by the end of therapy. As shown in figure 4 , each case of sinus pain, nasal congestion, headache, sore throat, dental pain, postnasal drip, and sinus tenderness resolved before the end of therapy, and facial pressure, purulent nasal discharge, and cough had resolved by the first visit after the end of therapy (7-14 days after the end of therapy). At 48 h and 72 h after the initiation of therapy, the median proportion of all infection signs and of all symptoms within patients that had resolved were 67% and 81%, respectively. The time to sinus sterilization was correlated with the median time to resolution of all infection signs and symptoms within patients (Spearman rank-order correlation coefficient, 0.83). The median sinus AUC:MIC ratio for gatifloxacin against the 4 pneumococcal isolates was 122.8 (range, 59. 4-218.8) .
Sample size calculations. We suspected that future comparative clinical trials could be conducted with fewer patients than are required for the traditional paradigm if the continuous end point of time to eradication was used instead of clinical cure or failure. Table 3 shows sample size calculations for trials based on observations from the current study. For a clinical trial comparing gatifloxacin with a new compound, the median time to bacteriologic eradication for gatifloxacin was 50 h, and a new compound might be considered superior to gatifloxacin if it reduced the median time to eradication by 24 h. Assuming a type I error rate (a) of 0.05 and a desired power of 90%, an accrual period of 6 months, and a 2-week follow-up period for each patient, 50 microbiologically evaluable patients per group are needed (scenario 2). Using cure or treatment failure in microbiologically evaluable patients as the primary end point and assuming an 85% clinical cure rate for gatifloxacin and a cure rate of 95% for clinical superiority, 200 patients per group would be needed. The reader should be cognizant that these sample size calculations are based on the assumption that all patients were microbiologically evaluable. Thus, these estimates would be larger when accounting for those patients with negative culture results.
DISCUSSION
The objective of this study was to quantify the time course of sinus sterilization and to describe organism exposure to gatifloxacin at the infection site, with the hypothesis that the use of a continuous and quantitative end point would allow for better characterization of drug effect. Using a SSAS technique, we successfully used the time to sinus sterilization as an end point and characterized organism exposure to gatifloxacin in maxillary sinus fluid. Subsequently, we used the median time to sinus sterilization and measurement of dispersion about the median for clinical trial sample size determination. We were able to demonstrate the opportunity for a clinical trial paradigm with fewer patients and to provide more-robust data than have traditional design approaches.
These data show that the use of a continuous and quantitative pharmacodynamic end point (the time to the sterilization of the infection site) rather than the dichotomous and nonspecific end points of cure and treatment failure can have a considerable impact on the number of patients required for a clinical trial. The consequence of using traditional clinical trial end points has been a limiting factor in our ability to characterize the true therapeutic effect of an antimicrobial agent. In the traditional paradigm for evaluation of antimicrobial regimens, both clinical and microbiological responses are determined after a period of observation following the end of therapy. Oftentimes, response to therapy is similar, and the challenge regimen is determined to be equivalent to the standard regimen. However, such study designs do not allow us to detect any differences between agents in regard to the rate of response. The only way to capture these differences is with the use of a time-related end point. Finally, the use of traditional clinical trial end points also allows for the potential misclassification of therapeutic response, inflates the number of patients required for clinical trials to prove efficacy, and ultimately increases the cost and complexity of conducting such trials. As expected, the time to resolution of all signs and symptoms of infection was somewhat longer than the time to sinus sterilization. In the case of sinusitis, signs and symptoms are caused by the interaction between the host and the infecting microorganism; up-regulation of inflammatory mediators in the nose, nasopharynx, and sinus; local immune response; and, in some patients, a deviated septum or an underlying chronic disease or allergies leading to mucosal changes. Even though bacterial eradication may occur at a given point in time, it takes additional time for signs and symptoms to significantly improve or completely resolve. In the clinical trial situation, lingering signs and symptoms of infection may lead the clinician to misclassify therapeutic response or, in the clinic, cause the physician to prescribe unnecessarily prolonged courses of therapy. The observations in this study may help define the optimal duration of antimicrobial treatment, and they support the notion of symptomatic therapy and clinical observation following antimicrobial therapy. In our analysis, there were too few patients to demonstrate a relationship between measurements of organism exposure to gatifloxacin (AUC:MIC, peak:MIC, time above MIC) and time to clinical and microbiological response. In a prior investigation [14] of gatifloxacin and levofloxacin in patients with community-acquired respiratory tract infection involving S. pneumoniae, AUC:MIC ratios of у34 were associated with a high probability of microbiological eradication, whereas ratios of !34 were associated with a lower probability of response. In the current analysis, AUC:MIC ratios in sinus fluid samples were ∼60 or greater in each instance. Given these findings, it is not unexpected that bacteria were eliminated rapidly from the infection site.
Previously, there have been a number of noteworthy investigations [15, 16] , either retrospective or prospective in design, that related measurement of organism exposure to an antibiotic in the plasma of individual patients to clinical and microbiological outcome to construct exposure-response relationships. The resultant paradigm shift accelerated the use of pharmacokinetic and pharmacodynamic modeling in clinical drug development of anti-infective agents to determine optimal treatment regimens. Serial sampling at the infection site may allow for another paradigm shift by reducing the number of patients required to demonstrate efficacy. It is interesting to note that in the current study, drug exposure, as described by the 24-h AUC, was greater in sinus fluid samples (median, 54.7 mg ϫ h/L) than in plasma samples (median, 30.1 /L). Estimg ϫ h mation of organism exposure to an antimicrobial agent at the infection site rather than in plasma may further refine the construct of exposure-response relationships. The FDA is encouraging the development of valid pharmacodynamic-based study designs during drug development in return for a reduction in the total number of clinical trials required for registration. Clinical trial data that can provide insight about relevant pharmacokinetic-pharmacodynamic relationships are far superior to approaches based on nonspecific outcomes. Unlike the therapeutic goal of treatments for other human ailments, which attempt to modulate physiologic systems, the goal of antimicrobial therapy is simply to kill microorganisms. The conditions under which an antimicrobial agent is effective can be carefully studied in nonclinical models of infection, such as in vitro and animal infection models, and efficacy can then be demonstrated in a small number of patients using a valid pharmacodynamic model. Although this paradigm would require relatively few patients in order to demonstrate efficacy, it still requires large numbers of patients in order to demonstrate safety. It is likely, however, that safety trials could be constructed that use study designs far different than traditional clinical trial designs and are powered to address specific safety concerns.
In conclusion, using an SSAS technique, we were able to quantify the time course of sterilization at the primary infection site for acute maxillary sinusitis and to describe gatifloxacin exposure in sinus fluid samples. The use of continuous and specific measurements of drug effect had a significant effect on clinical trial sample size calculations. Collection of these types of data in larger sinusitis trials and, when technically feasible, in other indications will allow for the development of drug exposure-response relationships with data specific to the infection site. Studies encompassing these design elements hold the promise of reducing the total number of patients required in order to demonstrate therapeutic efficacy. Because efficacy can be established with fewer patients, more resources can be applied to study the safety of antimicrobial agents.
